Financials

This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  COMPANY NAME assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQANIK
Beta1.11
Shares Outstanding14.5M
Average Volume (10 days)135.3K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($0.11)
Sales (TTM)$10.33
Book Value (MRQ)$19.65
Cash Flow (TTM)$0.61
Cash (MRQ)$6.24

Analyst Views

Current Mean RecommendationHold
Strong Buy0
 
Buy0
 
Hold3
 
Underperform0
 
Sell0
 

Recent Insider Transactions

David Colleran
EVP, General Counsel, Corp Sec
1,500
Buy
May 11, 2022
David Colleran
EVP, General Counsel, Corp Sec
1,500
Buy
Mar 14, 2022
Jeffery Scott Thompson
Director
2,000
Buy
Mar 11, 2022
Michael L. Levitz
EVP, CFO, Treasurer
4,000
Buy
Mar 11, 2022
Cheryl R. Blanchard
Director, President, CEO, Director
4,287
Buy
Mar 11, 2022

Recent SEC Filings

Insider Buy/Sell
May 12, 2022
DEFA14A
May 9, 2022
Quarterly Financials
May 6, 2022
Company Events
May 5, 2022
Insider Buy/Sell
Apr 28, 2022
To Top